HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2006. Nymox reported a net loss of $1,238,833, or $0.04 per share for the quarter ending September 30, 2006, compared to $958,464, or $0.04 per share for same period in 2005. The increase in the net loss is attributable to stock-based compensation costs ($282,063 compared to $4,055 for the same period in 2005) and to an increase in research and development expenditures (15% increase compared to the same period in 2005). Product sales amounted to $141,013 for the third quarter of 2006, compared to $100,110 for the same period in 2005. Nymox currently has $9.45 million in financing available from its most recent October 21, 2005 financing. The weighted diluted average number of common shares for the quarter ending September 30, 2006 was 27,789,196, compared to 25,916,670 for the same period in 2005.
